Although case reports have suggested a benefit for the treatment of refractory TTP (73, 320), possibly by eliminating autoreactive plasma cells producing anti-ADAMTS13 antibodies (321), prospective clinical trials are needed to investigate the effectiveness of this drug in the treatment of refractory TTP. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.